688189，被证监会立案！

Group 1 - The core point of the news is that Nanjing Pharmaceutical (688189) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations in annual report information disclosure [1] - The company announced the termination of a major asset restructuring plan, which was initiated on August 26 with Future Pharmaceutical companies, due to failure to reach consensus on core terms of the transaction [4] - Nanjing Pharmaceutical has experienced significant financial difficulties, reporting net losses for four consecutive years from 2021 to 2024, with net profits of -162 million, -78.83 million, -10.87 million, and -357 million respectively, while revenue declined from 744 million to 263 million [4] Group 2 - In the first half of 2025, Nanjing Pharmaceutical reported revenue of 61.84 million, a year-on-year decrease of 71.28%, and a net loss of 40 million, a decline of 493.23% compared to the previous year [5] - The company attributed its performance fluctuations to continuous price reductions of certain products, a decrease in flu cases, and insufficient market demand, leading to a lower sales proportion of high-margin products [5]